Chugai Pharmaceutical Co. Ltd. has signed a collaboration agreement with GSK plc’s Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody. Under this agreement, GSK GH will perform activities and explore potential funding for the initiation of clinical studies of AID-351.
The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV infections are urgently needed.
Zika virus (ZIKV), Dengue virus (DENV) and yellow fever virus (YFV) are closely related mosquito-borne flaviviruses for which effective treatment or prophylactic options are still scarce.
Researchers from Tan Tock Seng Hospital presented data from a study investigating the utility of soluble suppressor of tumorigenicity-2 (sST2) as early prognostic biomarker of severe dengue.
In a move to widen global access to its Qdenga dengue vaccine, Takeda Pharmaceutical Co. Ltd. is partnering with India’s Biological E. Ltd. to manufacture Qdenga (TAK-003).
In a move to widen global access to its Qdenga dengue vaccine, Takeda Pharmaceutical Co. Ltd. is partnering with India’s Biological E. Ltd. to manufacture Qdenga (TAK-003).
Previous research has shown that upon activation, platelets release CXCL4, influencing replication and propagation of dengue virus (DENV) by increasing the capacity of DENV-2 subtype to bind the CXCR3 receptor on monocytes. At the recent Viruses conference held in Barcelona, researchers from the Translational Health Science & Technology Institute reported the preclinical profile of a CXCR3 antagonist under investigation for the treatment of DENV.
Researchers from Hokkaido University (Japan) and colleagues have identified 2-thiouridine (s2U) as a broad-spectrum antiviral ribonucleoside analogue, by phenotypic screening of a library of 753 nucleoside analogues for antiviral effects. s2U showed antiviral activity against several ssRNA+ viruses, including DENV, SARS-CoV-2 and its variants of concern.
Codagenix Inc. announced that the U.S. Department of Defense (DoD), through the U.S. Army Medical Research and Development Command and the U.S. Army Medical Research Acquisition Activity, has awarded the company $5.88 million to advance the development of its Codavax-Denv, a tetravalent live attenuated dengue vaccine program.
